Shandong Sino Pharmaceutical Technology Co., Ltd.

We are supplying all of our  foreign customers with Customized Pharmaceutical Formulations or Dosage Forms.

You can tell us any pharmaceutical product, no matter what it is that you want. And then we will give you a detailed solution as per your requirement.  

We are always providing our customers with Consignment Manufacturing Serivce, OEM/ODM.

Product Application:
Insulin Glargine Injection is a long-acting insulin analogue prepared by recombinant DNA technology. It is mainly used for basal blood glucose control in type 1/2 diabetes. A subcutaneous injection once daily can provide a stable and peak-free blood drug concentration for 24 hours. The risk of hypoglycemia is lower than that of medium-acting insulin


1. Mechanism of action and indications

Long-term mechanism: After subcutaneous injection of acidic injection (pH≈4), micro-precipitates are formed at physiological pH, slowly releasing monomer insulin, achieving stable blood sugar control for 24 hours without obvious blood drug peaks, and reducing the risk of hypoglycemia at night.
Core indications: Type 1 and type 2 diabetes in adults, basic blood glucose control for type 1 diabetes in children aged 6 and above; It is not suitable for acute complications such as diabetic ketoacidosis and hyperglycemic hyperosmolar coma.
Contraindications and caution: Contraindicated for those allergic to insulin glargine or excipients. Patients with impaired liver or kidney function, the elderly, and those during pregnancy or lactation should adjust the dosage and enhance blood glucose monitoring.

The administration method is subcutaneous injection (abdomen/thigh/upper arm), once a day at the same time. Intravenous injection or mixing with other insulins is not allowed

The individualized starting dose for dose adjustment should be reduced by 20% to 30% from the first-week dose when switching to NPH insulin, and titrated step by step according to blood glucose

The efficacy features: It can stably control fasting blood glucose for 24 hours, and the risk of hypoglycemia is lower than that of medium-acting insulin. The steady-state concentration is reached 2 to 4 days after injection

Common adverse reactions include hypoglycemia (the most common), injection site reactions (redness/pain/itching), and fat hyperplasia, mostly mild to moderate

Global Supplier and Exporter:
Shandong Sino Pharmaceutical Technology Co.,Ltd.
North of National Road 327, Liuhang Town, High-tech Zone, Jining, China.

Payment:  T/T or west union
Delivery time: within 2 working days for ready stocks, 45 working days for batch order.
Shipment: HKEMS,TNT,UPS,door to door service for some countries.